secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001809519-26-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx reports Q4 revenue $194.8M, Adj. EBITDA $65.0M; Pharma Direct grows >40% YoY for 2025
--------------------------------------------------------------------------------

- Q4 2025 revenue $194.8M, net income $5.4M, Adjusted EBITDA $65.0M (33.4% margin).
- Full-year 2025 revenue $796.9M, net income $30.4M, Adjusted EBITDA $270.5M (33.9% margin).
- Pharma Direct revenue beat prior outlook with over 40% year-over-year growth in 2025.
- CEO Wendy Barnes notes strong finish, rebranded Pharma Manufacturer Solutions as Pharma Direct.
- Adjusted Net Income Q4 $29.0M (14.9% margin); FY $126.1M (15.8% margin).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951926000028/0001809519-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951926000028/gdrx-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001809519-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer